SMT201600078B - Antagonista del recettore per cgrp - Google Patents
Antagonista del recettore per cgrpInfo
- Publication number
- SMT201600078B SMT201600078B SM201600078T SM201600078T SMT201600078B SM T201600078 B SMT201600078 B SM T201600078B SM 201600078 T SM201600078 T SM 201600078T SM 201600078 T SM201600078 T SM 201600078T SM T201600078 B SMT201600078 B SM T201600078B
- Authority
- SM
- San Marino
- Prior art keywords
- antagonist
- cgrp receptor
- cgrp
- receptor
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901510P | 2010-03-30 | 2010-03-30 | |
| PCT/US2011/028168 WO2011123232A1 (en) | 2010-03-30 | 2011-03-11 | Cgrp receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600078B true SMT201600078B (it) | 2016-04-29 |
Family
ID=43896902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600078T SMT201600078B (it) | 2010-03-30 | 2016-03-21 | Antagonista del recettore per cgrp |
Country Status (29)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| WO2020077038A1 (en) * | 2018-10-13 | 2020-04-16 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of cgrp antagonists |
| KR20210116560A (ko) * | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
| SG11202111251SA (en) | 2019-04-11 | 2021-11-29 | R P Scherer Technologies Llc | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
| CN114980862A (zh) * | 2019-12-17 | 2022-08-30 | 拜尔哈文制药股份有限公司 | Cgrp抑制剂的鼻内药物组合物 |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び／又は発生の低減 |
| WO2022217008A1 (en) | 2021-04-09 | 2022-10-13 | Teva Czech Industries S.R.O | Solid state forms of zavegepant and process for preparation thereof |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| US20240366618A1 (en) * | 2021-10-11 | 2024-11-07 | Pfizer Ireland Pharmaceuticals | CGRP Antagonists for Treating Trigeminal Neuralgia |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
| US20250276959A1 (en) | 2022-11-09 | 2025-09-04 | Teva Czech Industries S.R.O. | Solid state forms of zavegepant hydrochloride and process for preparation thereof |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
| JP2026515029A (ja) | 2023-04-28 | 2026-05-13 | 成都思倍博医▲薬▼科技有限公司 | オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用 |
| WO2025003905A1 (en) | 2023-06-29 | 2025-01-02 | Pfizer Inc. | Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide |
| CN119462607B (zh) * | 2023-08-10 | 2025-11-28 | 南京宁丹新药技术股份有限公司 | 一类喹啉酮衍生物及其用途 |
| EP4781986A1 (en) | 2023-09-21 | 2026-07-29 | Sichuan Purity Pharmaceutical Co., Ltd. | Pharmaceutical composition having improved pharmacokinetic properties |
| CN117551081A (zh) * | 2023-11-13 | 2024-02-13 | 北京康立生医药技术开发有限公司 | 一种偏头痛治疗药物新的制备方法 |
| ES3027457A1 (es) * | 2023-12-13 | 2025-06-13 | Moehs Iberica Sl | Metodo de preparacion de zavegepant, intermedios de sintesis de zavegepant y metodos de preparacion de los mismos |
| IT202400011158A1 (it) | 2024-05-16 | 2025-11-16 | Olon Spa | Processo per preparare (r)-2-ammino-3-(7-metil-1h-indazol-5-il) propanoato di metile, e suo uso come intermedio per la sintesi di zavegepant. |
| WO2026033478A1 (en) | 2024-08-09 | 2026-02-12 | Olon S.P.A. | Process for preparing 3-piperidin-4-il-1h- quinolin-2-one or a salt thereof and its use as an intermediate for the preparation of pharmaceutical active ingredients antagonists of the cgrp peptide receptor |
| CN119306698B (zh) * | 2024-10-09 | 2025-10-21 | 浙江工业大学 | 一种制备扎维吉泮中间体的新方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| ES2616539T3 (es) * | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| CN101495480B (zh) * | 2006-05-03 | 2013-07-10 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
| WO2010006168A2 (en) | 2008-07-09 | 2010-01-14 | University Of Rochester | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
-
2011
- 2011-03-02 US US13/038,550 patent/US8481546B2/en active Active
- 2011-03-11 PE PE2012001746A patent/PE20130340A1/es active IP Right Grant
- 2011-03-11 MX MX2012010725A patent/MX2012010725A/es active IP Right Grant
- 2011-03-11 ES ES11710087.5T patent/ES2562610T3/es active Active
- 2011-03-11 SG SG2012065744A patent/SG183918A1/en unknown
- 2011-03-11 JP JP2013502610A patent/JP5908455B2/ja active Active
- 2011-03-11 BR BR112012024785-9A patent/BR112012024785B1/pt active IP Right Grant
- 2011-03-11 AU AU2011233627A patent/AU2011233627B2/en active Active
- 2011-03-11 CA CA2794950A patent/CA2794950C/en active Active
- 2011-03-11 WO PCT/US2011/028168 patent/WO2011123232A1/en not_active Ceased
- 2011-03-11 KR KR1020187011875A patent/KR20180049168A/ko not_active Ceased
- 2011-03-11 EP EP11710087.5A patent/EP2552906B1/en active Active
- 2011-03-11 KR KR1020177015456A patent/KR101854249B1/ko active Active
- 2011-03-11 DK DK11710087.5T patent/DK2552906T3/en active
- 2011-03-11 PL PL11710087T patent/PL2552906T3/pl unknown
- 2011-03-11 RS RS20160164A patent/RS54608B1/sr unknown
- 2011-03-11 NZ NZ603231A patent/NZ603231A/en unknown
- 2011-03-11 PT PT117100875T patent/PT2552906E/pt unknown
- 2011-03-11 SI SI201130765A patent/SI2552906T1/sl unknown
- 2011-03-11 KR KR1020127028213A patent/KR101747477B1/ko active Active
- 2011-03-11 CN CN201180016888.2A patent/CN102834388B/zh active Active
- 2011-03-11 EA EA201270751A patent/EA022815B1/ru not_active IP Right Cessation
- 2011-03-11 HU HUE11710087A patent/HUE028735T2/en unknown
- 2011-03-11 HR HRP20160287TT patent/HRP20160287T1/hr unknown
- 2011-03-30 AR ARP110101057A patent/AR080746A1/es not_active Application Discontinuation
- 2011-03-30 TW TW100111106A patent/TWI483937B/zh active
-
2012
- 2012-08-27 IL IL221665A patent/IL221665A/en active IP Right Grant
- 2012-09-28 ZA ZA2012/07292A patent/ZA201207292B/en unknown
- 2012-09-28 CL CL2012002739A patent/CL2012002739A1/es unknown
-
2016
- 2016-03-21 SM SM201600078T patent/SMT201600078B/xx unknown
- 2016-03-24 CY CY20161100254T patent/CY1117593T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200033I1 (hu) | CGRP receptor antagonisták | |
| CY2023022I1 (el) | Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης | |
| ZA201207292B (en) | Cgrp receptor antagonist | |
| EP2911675A4 (en) | 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS | |
| EP2803662A4 (en) | P2X4 Receptor Antagonists | |
| DK2443104T3 (da) | Disubstituerede phthalazin-hedgehog-sti-antagonister | |
| PL2928870T3 (pl) | Ligandy receptora neurotensyny | |
| EP2709991A4 (en) | USE OF CXCR4 ANTAGONISTS | |
| DK3312169T3 (da) | 5-ht3 receptorantagonister | |
| SMT201500296B (it) | Antagonisti del recettore trpm8 | |
| EP2665707A4 (en) | ANTAGONISTS OF THE MINERALOCORTICOID RECEPTOR | |
| ZA201306744B (en) | Antagonists of the interleukin-1 receptor | |
| SMT201500293B (it) | Antagonisti del recettore toll-like 3 | |
| IL244356B (en) | Formulations for cgrp receptor antagonists | |
| EP2654421A4 (en) | CONDENSED HETEROCYCLIC INDAN CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | |
| EP2771346A4 (en) | ISOXAZOLOPYRIDIN-orexin | |
| EP2566494A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
| EP2458991A4 (en) | RADIOACTIVELY MARKED CGRP ANTAGONISTS | |
| EP2888261A4 (en) | ANTAGONISTS OF CHEMOKIN RECEPTORS | |
| BR112015005750A2 (pt) | antagonistas peptídicos do receptor de vasopressina-2 | |
| EP2846800A4 (en) | HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | |
| EP2408304A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
| FI9140U1 (fi) | Välipohjarakenne |